CA3141414A1 - Dibenzylamines as amino acid transport inhibitors - Google Patents

Dibenzylamines as amino acid transport inhibitors Download PDF

Info

Publication number
CA3141414A1
CA3141414A1 CA3141414A CA3141414A CA3141414A1 CA 3141414 A1 CA3141414 A1 CA 3141414A1 CA 3141414 A CA3141414 A CA 3141414A CA 3141414 A CA3141414 A CA 3141414A CA 3141414 A1 CA3141414 A1 CA 3141414A1
Authority
CA
Canada
Prior art keywords
amino
compound
cancer
benzyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141414A
Other languages
English (en)
French (fr)
Inventor
H. Charles Manning
Michael Schulte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CA3141414A1 publication Critical patent/CA3141414A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3141414A 2019-06-12 2020-06-12 Dibenzylamines as amino acid transport inhibitors Pending CA3141414A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860571P 2019-06-12 2019-06-12
US62/860,571 2019-06-12
PCT/US2020/037527 WO2020252336A1 (en) 2019-06-12 2020-06-12 Dibenzylamines as amino acid transport inhibitors

Publications (1)

Publication Number Publication Date
CA3141414A1 true CA3141414A1 (en) 2020-12-17

Family

ID=71409525

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141414A Pending CA3141414A1 (en) 2019-06-12 2020-06-12 Dibenzylamines as amino acid transport inhibitors

Country Status (7)

Country Link
US (1) US20220265590A1 (enExample)
EP (1) EP3983377A1 (enExample)
JP (1) JP2022536728A (enExample)
CN (1) CN114269715A (enExample)
AU (1) AU2020291936A1 (enExample)
CA (1) CA3141414A1 (enExample)
WO (1) WO2020252336A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CA3112129A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
CA3148745A1 (en) 2019-08-29 2021-03-04 Xiaolun Wang Kras g12d inhibitors
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
US12286431B2 (en) 2020-09-11 2025-04-29 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20240174658A1 (en) * 2021-03-01 2024-05-30 Vanderbilt University Heteroaromatic Inhibitors of Cancer Metabolism
KR102635329B1 (ko) * 2021-07-21 2024-02-13 경북대학교 산학협력단 혈관평활근세포의 증식 또는 이동 억제 효과를 갖는 화합물을 유효성분으로 포함하는 혈관평활근세포 이상 증식성 질환의 예방 또는 치료용 약학적 조성물
CN117466761B (zh) * 2022-07-21 2026-04-28 中国药科大学 谷氨酰胺转运抑制剂、药物组合物和应用
CN116410152B (zh) * 2023-04-13 2023-11-03 江苏征瑞医药科技有限公司 一种抑制asct2的小分子化合物、其衍生物及其应用
CN117550997B (zh) * 2023-11-09 2025-12-19 中国药科大学 一种lat1抑制剂及其制法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501692A (enExample) 1980-09-24 1982-09-16
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US10280221B2 (en) 2013-03-15 2019-05-07 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
CN105873606B (zh) 2013-09-11 2020-12-29 米迪缪尼有限公司 用于治疗肿瘤的抗b7-h1抗体
US20150252434A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2018107173A1 (en) * 2016-12-09 2018-06-14 Vanderbilt University Glutamine transport inhibitors and methods for treating cancer

Also Published As

Publication number Publication date
EP3983377A1 (en) 2022-04-20
CN114269715A (zh) 2022-04-01
US20220265590A1 (en) 2022-08-25
JP2022536728A (ja) 2022-08-18
WO2020252336A1 (en) 2020-12-17
AU2020291936A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US20220265590A1 (en) Dibenzylamines as amino acid transport inhibitors
US20220304984A1 (en) Amino acid transport inhibitors and the uses thereof
JP7459149B2 (ja) Ｔｇ０２によるがん治療
US20220388978A1 (en) Cereblon e3 ligase inhibitors
KR20230074721A (ko) Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
TWI785098B (zh) Tg02之多晶型
CA3126822A1 (en) Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
US20240174658A1 (en) Heteroaromatic Inhibitors of Cancer Metabolism
US20220332676A1 (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof
WO2022261117A1 (en) Combination therapy with a don prodrug and a tigit inhibitor
EP4267136A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
WO2022072820A1 (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
WO2021026395A1 (en) Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance
HK40030306A (en) Polymorphic form of tg02

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927